Suzuki Hidekazu, Nishizawa Toshihiro, Tsugawa Hitoshi, Hibi Toshifumi
Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan.
Keio J Med. 2012;61(4):109-19. doi: 10.2302/kjm.2012-0001-re.
Thirty years have passed since Warren and Marshall's discovery of Helicobacter pylori (H. pylori). Since then, not only peptic ulcer diseases and chronic gastritis but also non-cardia gastric cancers have been recognized as diseases originating from H. pylori infection. Several combination therapies consisting of multiple antibiotics have been developed as first- or second-line regimens to eradicate H. pylori infection. Our extensive experience in the field of anti-H. pylori medicine suggests that clinicians should consider a possible role for unidentified, invisible pathogens to elucidate the pathogenesis and improve the treatment of refractory diseases of unknown etiology.
自沃伦和马歇尔发现幽门螺杆菌（H. pylori）以来，已经过去了三十年。从那时起，不仅消化性溃疡疾病和慢性胃炎，而且非贲门胃癌都被认为是由幽门螺杆菌感染引起的疾病。已经开发了几种由多种抗生素组成的联合疗法作为根除幽门螺杆菌感染的一线或二线方案。我们在抗幽门螺杆菌医学领域的丰富经验表明，临床医生应考虑未识别的、不可见病原体在阐明发病机制和改善病因不明的难治性疾病治疗方面可能发挥的作用。
